Increasing high-density lipoprotein cholesterol levels for cardiovascular benefit: The end of a dream?

Abstract

Get full access to this article

View all access options for this article.

References

Emerging Risk Factors Collaboration Di Angelantonio

Sarwar

Perry

et al.

Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302: 1993–2000.

Remaley

Norata

Catapano

. Novel concepts in HDL pharmacology. Cardiovasc Res 2014; 103: 423–428.

Voight

Peloso

Orho-Melander

et al.

Plasma HDL cholesterol and risk of myocardial infarction: A Mendelian randomisation study. Lancet 2012; 380: 572–580.

Madsen

Varbo

Nordestgaard

. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: Two prospective cohort studies. Eur Heart J 2017; 38: 2478–2486.

Riaz H, Khan SU, Rahman H, et al. Effects of high density lipoprotein targeting treatments on cardiovascular outcomes: A systematic review and meta-analysis. Eur J Prev Cardiol. 2019; 26: 533–543.

Jin

Gao

et al.

Effects of add-on lipid-modifying therapy on top of background statin treatment on major cardiovascular events: A meta-analysis of randomized controlled trials. Int J Cardiol 2015; 191: 138–148.

Varbo

Benn

Tybjaerg-Hansen

et al.

Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 2013; 61: 427–436.

Sniderman

Couture

Martin

et al.

Hypertriglyceridemia and cardiovascular risk: A cautionary note about metabolic confounding. J Lipid Res 2018; 59: 1266–1275.

Ference

Kastelein

JJP

Ginsberg

et al.

Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk. JAMA 2017; 318: 947–956.